Bynder Kicks Off Peak Shopping Season by Serving a Record 6 Billion Assets - Powering Exceptional Global Content Experiences Online
9.12.2024 16:07:00 CET | Business Wire | Press release
Bynder, a global leader in AI-powered enterprise DAM, has helped a number of global brands break Black Friday and Cyber Monday records by delivering exceptional content experiences at scale across a number of worldwide e-commerce channels.
During the seven day period (November 27 - Dec 2 2024) which included Black Friday, Small Business Saturday, and Cyber Monday, Bynder’s Content Experiences (CX) for Omnichannel solution was responsible for serving more than 6 billion assets to over 70,000 websites, with more than 4.5 billion asset transformations undertaken.
The figures represent a 15% increase in assets delivered vs 2023, plus 67% more assets were delivered through CX for Omnichannel on Black Friday than an average day in 2024.
Customers such as Sur La Table, Bose, Raymour & Flanigan and Puma used CX for Omnichannel to deliver targeted and optimized content at scale to their digital channels over the busiest shopping days. Bynder customers were able to utilize the assets stored in their Bynder DAM and transform and deliver them to their digital channels, including their website, e-commerce sites, emails and social media.
Bynder’s DAM sits at the heart of a brand’s martech stack as the system of record for digital assets, while Bynder’s CX for Omnichannel solution is the delivery technology that connects the DAM to a brand’s tech ecosystem and automates delivering optimized assets for each digital channel in real time.
For consumer brands that are delivering seasonal shopping content across a number of e-commerce platforms, Bynder’s solution can transform, optimize and deliver targeted content experiences based on the channel and audience automatically, that boost return on investment all while ensuring brand consistency, improved website performance and increase in conversions for e-commerce sites.
According to a NielsenIQ study analyzed by Barcelona's OBS Business School, Black Friday has become one of the most anticipated European retail periods in the run-up to the holiday season, with 61% of consumers in Spain, the UK, Italy, France, and Germany expected to have participated in Black Friday. While in the US, a record 200.4 million consumers shopped over the five-day holiday weekend from Thanksgiving Day through Cyber Monday, surpassing last year’s record of 196.7 million.
When creating and managing seasonal assets, a survey by Bynder revealed that 51% of marketers agreed that more marketing assets are required for Black Friday than any other seasonal holiday. The biggest challenge stated for just over one in three (36%) respondents was managing the number of assets they were creating for the peak shopping season.
Sur La Table, a retailer known for a variety of upscale cooking and dining supplies, is one such brand scaling its content delivery through Bynder during the holiday peak period.
Blake Bakanoff, VP of Creative at Sur La Table, said, “A good tool improves the way we work. A great partner improves the way we think, make and move.At Sur La Table, bringing value to our customers, by creating exceptional culinary content, lies at the core of our brand. We’re “Makers” at heart, and Bynder’s CX for Omnichannel solution empowers us to create, adapt, and deliver a wealth of custom content tailored to every channel—whether it’s showcasing thoughtful gift ideas on Instagram, sharing original holiday recipes through email, or engaging customers as they explore our website. By connecting our teams and external partners to our extensive content catalog delivering 165M+ assets, Bynder enables us to inspire and delight our customers with curated, memorable experiences during the peak holiday season."
Peter-Paul Houtman, CTO at Bynder, said: “The period between Thanksgiving and Cyber Monday represents some of the busiest days for e-commerce retailers. The volume of shoppers has increased over time and so has the volume of products that are available at a discount. E-commerce retailers are dealing with a higher volume of transactions and they need a scalable AI-powered enterprise grade platform like Bynder’s DAM, as well as its Content Experiences (CX) for Omnichannel solution, to deliver exceptional content experiences for their customers during these peak times.
“A unified omnichannel approach in terms of managing assets and delivering assets digitally ensures no opportunity is missed during peak retail seasons and by using Content Experiences for Omnichannel, leading brands can supercharge their marketing strategies and boost engagement by creating targeted content experiences across a number of digital touchpoints, improving website performance and conversions to bring real return-on-investment to businesses.”
For more information on Bynder’s DAM, please visit: https://www.bynder.com/en/products/digital-asset-management/ and for more information on Content Experiences (CX) for Omnichannel, please visit: https://www.bynder.com/en/products/content-experiences-for-omnichannel/
View source version on businesswire.com: https://www.businesswire.com/news/home/20241209828157/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom